NARBERTH, PA — Chou2 Pharma LLC has announced the launch of a new study in collaboration with Ethos Discovery to evaluate the pharmacokinetics of a potential proprietary drug for treating idiopathic epilepsy in dogs. The study, set to begin early this year, will lay the groundwork for a subsequent proof-of-concept efficacy study in dogs diagnosed with epilepsy.
The experimental therapy is built on Chou2 Pharma’s precision cannabinoid formulating platform, aiming to address a condition that affects many dogs and often proves difficult to manage. Idiopathic epilepsy remains a significant challenge in veterinary medicine, with 30-40% of affected dogs showing resistance to available treatments, resulting in frequent or severe seizures. Existing treatment options often involve a combination of drugs, which can lead to severe side effects, potentially diminishing the quality of life for these animals.
“We are extremely excited to be working with Dr. Khanna and his team at Ethos Discovery,” said Brian Segebrecht, CEO of Chou2 Pharma. “Partnering with an organization like Ethos Discovery in the early stages of developing this new potential companion animal drug is critical to our ultimate goal of utilizing our unique platform for treating more pets with therapeutic needs that are underserved.”
For Chou2 Pharma, this study reflects the company’s vision of advancing veterinary medicine. Co-founder and Executive Chairman John Payne noted, “It’s rewarding to see our vision coming to life in such an important therapeutic area. Ethos Discovery is a highly respected research organization, and we look forward to working with them on this study, and more studies in the future as we expand upon the full therapeutic potential of cannabinoid molecules in veterinary medicine.”
This partnership represents a promising step forward in veterinary pharmaceuticals. Dr. Khanna from Ethos Discovery highlighted the unmet need in this area, stating, “This is a therapeutic area of veterinary medicine that would greatly benefit from an improved drug that is more consistently effective and comes with a stronger safety profile. We hope that with our preliminary work with Chou2 on their new potential drug intended to target idiopathic epilepsy, we can help to achieve that for veterinary medicine.”
The study’s outcomes could pave the way for innovative treatments, offering hope to dog owners and veterinarians alike in managing epilepsy while improving the well-being of pets.
For the latest news on everything happening in Chester County and the surrounding area, be sure to follow MyChesCo on Google News and MSN.